1:1 Bonus Shares: Board of This Pharma Stock Unveils Revised Record Date; Should You Give Buying Interest?

The revised record date for the upcoming corporate action in the form of bonus shares has been declared by the board of directors of Shilpa Medicare, a small-cap pharmaceutical company. Established in 1987, Shilpa Medicare is a multinational pharmaceutical corporation with a focus on the creation, production, and distribution of generic medications, biosimilars, and active pharmaceutical ingredients (APIs). Shilpa Medicare, which has its headquarters in Hyderabad, India, provides services to a number of regulated markets throughout the globe, including the USA, Europe, and Japan.

Shilpa Medicare Bonus Shares Record Date

"With reference to our earlier intimation dated 13 August 2025, we wish to inform you that in due compliance with BSE Circular dated 07 February 2025, the record date for the purpose of determining the eligibility of shareholders entitled to receive the Bonus Shares of the Company is revised to 03 October 2025," said the company in a stock exchange filing on 22nd August.

Earlier, Friday, 26th September, 2025 was fixed as the record date for determining the entitlement of members of the company to receive bonus equity shares.

Shilpa Medicare Bonus Shares Details

"The Board of Directors in its meeting held on 13th August, 2025 have inter alia considered and recommended the Issue of Bonus equity shares by capitalizing a sum of Rs. 9,77,90,908 (Rupees Nine Crores SeventySeven Lakhs Ninety Thousand Nine hundred and eight only) out of the Company's securities premium account in the ratio 1:1 i.e. 1 (One) equity share of Rs. 1/- each for every 1 (One) full paid-up equity share of Rs. 1/- each held by the Shareholders of the Company as on the Record Date, subject to the approval of Shareholders in the ensuing AGM," Shilpa Medicare confirmed in a regulatory filing.

"The paid-up capital as on date is Rs. 9,77,90,908 and post bonus issue (upon the members approval in the ensuing AGM) would be increased to Rs. 19,55,81,816. The estimated date by which such bonus shares would be credited/dispatched is within two months of declaration of Bonus shares," Shilpa Medicare highlighted in a statement.

Shilpa Medicare Upcoming Dividend

For FY 2024-2025, the Board has decided to pay a dividend of Re. 1.00/- (100%) every equity share with a face value of Rs. 1/-each.

"This is further to our intimation dated May 26, 2025, wherein it was informed that the Board of Directors of the Company had, inter alia, recommended a final dividend for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM). In this connection, pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015, it is hereby informed that the Record Date has been fixed as Wednesday, 17 September 2025, for determining the entitlement of shareholders to the final dividend. The final dividend, if approved by the shareholders at the ensuing AGM (scheduled to be held on 23rd September 2025), will be paid/dispatched within the statutory time limit from the date of approval," Shilpa Medicare said in a separate exchange filing.

Shilpa Medicare Q1FY26 Financials

According to Business Standard, Shilpa Medicare's net profit increased 233.50% to Rs 46.89 crore in the June 2025 quarter from Rs 14.06 crore in the June 2024 quarter. In Q1FY26, sales increased 9.90% to Rs 321.46 crore from Rs 292.51 crore in Q1FY25.

Shilpa Medicare Target Price

"Shilpa Medicare (CMP ₹839) has witnessed a healthy reversal from support zones, reflecting accumulation at lower levels and fresh buying interest. The immediate support lies near ₹820, while ₹800 serves as a crucial stop-loss for traders. If the stock sustains above current levels, it holds potential to move toward ₹880, with an extended target near ₹900. Improving price structure along with favorable momentum indicators suggests further upside in the coming sessions," commented Riyank Arora, technical analyst at Mehta Equities Ltd.

Disclaimer

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.